HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dinbergs, I. D. Articles by Edelman, E. R. Search for Related Content PubMed PubMed Citation Articles by Dinbergs, I. D. Articles by Edelman, E. R. Social Bookmarking                      What's this?

Volume 271, Number 47, Issue of November 22, 1996 pp. 29822-29829
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Cellular Response to Transforming Growth Factor-1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions

(Received for publication, March 19, 1996, and in revised form, September 4, 1996)

Iveta D. Dinbergs , Larry Brown and Elazer R. Edelman ^¶

From the  Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 and the ^¶ Department of Medicine, Cardiovascular Division, Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts 02115

The extracellular matrix plays an important role in growth factor biology, serving as a potential platform for rapid growth factor mobilization or a sink for concentrated sequestration. We now demonstrate that when a growth factor binds reversibly to the matrix, its effects are augmented by this interaction, and when the factor is absorbed irreversibly to the extracellular matrix, it becomes sequestered. These findings call into question the notion that all growth factors are best presented to cells and tissues in a sustained and controlled fashion. In our studies, we examined basic fibroblast growth factor (bFGF) and transforming growth factor-1 (TGF-1) release kinetics from synthetically fabricated microsphere devices and naturally synthesized extracellular matrix. While the sustained release of bFGF was up to 3.0-fold more potent at increasing vascular endothelial and smooth muscle cell proliferation than bolus administration, the reverse was true for TGF-1. A bolus of TGF-1 inhibited vascular cells up to 3.8-fold more efficiently than the same amount of TGF-1 if control-released. Both growth factors bound to the extracellular matrix, but only bFGF was released in a controlled fashion (2.8%/day). Contact with the extracellular matrix and subsequent release enhanced bFGF activity such that it was 86% more effective at increasing smooth muscle cell numbers than equal amounts of growth factor diluted from frozen stock. TGF-1 remained tightly adherent. The small amount of TGF-1 released from the extracellular matrix was ~30% less effective than bolus administration at inhibiting vascular endothelial and smooth muscle cell growth. Sustained growth factor release may be the preferable mode of administration, but only when a similar mode of metabolism is utilized endogenously.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Khalil, Y. D. Xu, R. O'Connor, and V. Duronio Proliferation of Pulmonary Interstitial Fibroblasts Is Mediated by Transforming Growth Factor-beta1-induced Release of Extracellular Fibroblast Growth Factor-2 and Phosphorylation of p38 MAPK and JNK J. Biol. Chem., December 30, 2005; 280(52): 43000 - 43009. [Abstract] [Full Text] [PDF]

				C. R. Harlow, M. Rae, L. Davidson, P. C. Trackman, and S. G. Hillier Lysyl Oxidase Gene Expression and Enzyme Activity in the Rat Ovary: Regulation by Follicle-Stimulating Hormone, Androgen, and Transforming Growth Factor-{beta} Superfamily Members in Vitro Endocrinology, January 1, 2003; 144(1): 154 - 162. [Abstract] [Full Text] [PDF]

				P E C Brenchley Antagonising angiogenesis in rheumatoid arthritis Ann Rheum Dis, November 1, 2001; 60(90003): iii71 - 74. [Full Text] [PDF]

				R. S. Kiesz, P. Buszman, J. L. Martin, E. Deutsch, M. M. Rozek, E. Gaszewska, M. Rewicki, P. Seweryniak, M. Kosmider, and M. Tendera Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial : Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) Circulation, January 2, 2001; 103(1): 26 - 31. [Abstract] [Full Text] [PDF]

				M. A. Lovich and E. R. Edelman Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo PNAS, September 28, 1999; 96(20): 11111 - 11116. [Abstract] [Full Text] [PDF]

				H. M. Nugent, C. Rogers, and E. R. Edelman Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty Circ. Res., March 5, 1999; 84(4): 384 - 391. [Abstract] [Full Text] [PDF]

				R. Lametsch, J. T. Rasmussen, L. B. Johnsen, S. Purup, K. Sejrsen, T. E. Petersen, and C. W. Heegaard Structural Characterization of the Fibroblast Growth Factor-binding Protein Purified from Bovine Prepartum Mammary Gland Secretion J. Biol. Chem., June 23, 2000; 275(26): 19469 - 19474. [Abstract] [Full Text] [PDF]